Don't MissASCO in 30: Wall Street’s reaction & patient-reported outcomes By Sharon Begley and Adam Feuerstein June 4, 2018 Reprints ASCO in 30: Wall Street’s reaction & patient-reported outcomes About the Authors Reprints Sharon Begley Senior Writer, Science and Discovery (1956-2021) Sharon covered science and discovery. @sxbegle Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast. [email protected] @adamfeuerstein
Don't Miss STAT Staff Introducing the 2023 STATUS List, the definitive accounting of leaders in the life sciences
Pharmalot Ed Silverman and Damian Garde STAT Plus: Shortage of monkeys for early-stage research jeopardizes timelines for developing some drugs
Special Report Brittany Trang STAT Plus: As AI promises to revolutionize medical note-taking, concerns mount about accuracy and harm
A STAT Investigation Casey Ross and Bob Herman STAT Plus: Denied by AI: How Medicare Advantage plans use algorithms to cut off care for seniors in need
